Clinical Trials
27 trialsNCT03710876 2026-04-21
INFINITE
Ferring Ventures Limited
Phase 3 Completed
NCT05136677 2026-01-23
CheckMate 6DW
Bristol-Myers Squibb
Phase 2 Completed
NCT05795595 2025-11-26
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
CRISPR Therapeutics
Phase 1/2 Completed
NCT04525859 2025-06-24
Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma
Oncovir, Inc.
Phase 1 Completed
NCT06469138 2025-01-29
8479217
BerGenBio ASA
Phase 1 Completed
NCT05324436 2025-01-20
A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)
Bristol-Myers Squibb
Completed
NCT04843007 2024-10-23
Alvopem® (Pemetrexed) Safety Assessment
NanoAlvand
Completed
NCT01265433 2024-10-09
Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy
Sellas Life Sciences Group
Phase 2 Completed
NCT05538572 2024-07-01
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
Prelude Therapeutics
Phase 1 Completed
NCT02709512 2023-10-04
ATOMIC
Polaris Group
Phase 2/3 Completed
NCT03507452 2023-03-20
First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin
Bayer
Phase 1 Completed
NCT04430842 2023-01-18
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
Phase 1 Completed
NCT00738582 2022-09-22
Amatuximab
Morphotek
Phase 2 Completed
NCT02347917 2022-04-12
A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma
Sumitomo Pharma Co., Ltd.
Phase 1/2 Completed
NCT01655225 2022-04-08
A Study of LY3023414 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT00700336 2021-07-20
Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
CanBas Co. Ltd.
Phase 1/2 Completed
NCT00535951 2020-12-19
Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma
Novartis
Phase 1 Completed
NCT01675765 2020-09-30
Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma
Aduro Biotech, Inc.
Phase 1 Completed
NCT03177668 2020-09-25
Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma
Kissei Pharmaceutical Co., Ltd.
Phase 1/2 Completed
NCT01098266 2019-09-17
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
AGC Biologics S.p.A.
Phase 3 Completed
NCT00484276 2019-01-16
NGR010
AGC Biologics S.p.A.
Phase 2 Completed
NCT01358084 2019-01-15
NGR019
AGC Biologics S.p.A.
Phase 2 Completed
NCT02397928 2018-09-25
Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)
NovoCure Ltd.
Phase 2 Completed
NCT01721018 2017-06-09
1716-12
Virttu Biologics Limited
Phase 1/2 Completed
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed
NCT00787410 2012-06-06
An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma
AstraZeneca
Phase 2 Completed
NCT00386815 2007-04-11
Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma
Eli Lilly and Company
Phase 2 Completed